Patents by Inventor Thomas Mandel Clausen

Thomas Mandel Clausen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTITHROMBIN HEPARAN SULFATE FOR DETECTION AND TREATMENT OF CANCER
    Publication number: 20240053342
    Abstract: Methods of detecting and treating an epithelial carcinoma, such as pancreatic ductal adenocarcinoma cancer or bladder cancer, expressing antithrombin-binding heparan sulfate (HSAT) in a subject, comprising combining a biological sample of the subject containing HSAT with antithrombin and detecting binding of HSAT and the antithrombin, optionally determining that the antithrombin inhibits factor Xa.
    Type: Application
    Filed: December 20, 2021
    Publication date: February 15, 2024
    Inventors: Ryan Weiss, Thomas Mandel Clausen, Jeffrey D. Esko
  • Targeting of chondroitin sulfate glycans
    Patent number: 11787844
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: October 17, 2023
    Assignee: VAR2 Pharmaceuticals APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • METHODS AND USES OF HALOFUGINONE
    Publication number: 20230321101
    Abstract: The present disclosure relates to treatment or prevention of a disease, such as COVID-19, in a subject by administering to the subject a therapeutically effective amount of halofuginone or a derivative or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 12, 2023
    Inventors: Philip L.S.M. Gordts, Andrea Denardo, Ryan Joseph Weiss, Chelsea Nora, Jeffrey D. Esko, Thomas Mandel-Clausen, Daniel R. Sandoval
  • APPLICATION OF MICROBIAL GLYCOSIDASE AS AN ANTI-VIRAL THERAPEUTIC, PROGNOSTIC, AND DIAGNOSTIC
    Publication number: 20230277634
    Abstract: Methods and compositions for diagnosing, preventing or treating a viral infection in a subject comprising administering to a subject in need thereof an effective amount of a glycosidase or a sulfatase to degrade a glycan, such as heparan sulfate, to inhibit viral infection, such as COVID-19. Methods for identifying a glycosidase, a sulfatase, or a microbe associated with increased susceptibility to viral infection in a subject.
    Type: Application
    Filed: August 16, 2021
    Publication date: September 7, 2023
    Inventors: Cameron Martino, Benjamin Kellman, Nathan Lewis, Robin Knight, Jeffrey D. Esko, Daniel Sandoval, Thomas Mandel Clausen
  • Targeting of chondroitin sulfate glycans
    Patent number: 9932375
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: April 3, 2018
    Assignee: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • Targeting of chondroitin sulfate glycans
    Patent number: 9926350
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 27, 2018
    Assignee: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • TARGETING OF CHONDROITIN SULFATE GLYCANS
    Publication number: 20170081373
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: October 5, 2016
    Publication date: March 23, 2017
    Applicant: VAR2 PHARMACEUTICAL APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • TARGETING OF CHONDROITIN SULFATE GLYCANS
    Publication number: 20170016905
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: October 5, 2016
    Publication date: January 19, 2017
    Applicant: VAR2 PHARMACEUTICAL APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • TARGETING OF CHONDROITIN SULFATE GLYCANS
    Publication number: 20150004099
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: February 8, 2013
    Publication date: January 1, 2015
    Applicant: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen